Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis

Journal of the American Academy of Dermatology

Volumn 43, Issue 4 SUPPL., 2000, Pages

  Gupta, Aditya K ^a,b,c   Fleckman, Philip ^a,b,c   Baran, Robert ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NAIL DISEASE CENTRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CICLOPIROX;

ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONYCHOMYCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOE;

EID: 0033784755     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.109071     Document Type: Article

References (25)

1. Antifungal agents: An overview. Part I
2. Antifungal agents: An overview. Part II
3. Current management of onychomycosis
4. Biochemical basis for the activity of oral antifungal drugs
5. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition
6. Hydroxy-pyridones outstanding biological properties
7. The hydroxypyridones: A class of antimycotics of its own
8. Therapy with ciclopirox lacquer of onychomycosis caused by molds
9. Hendersonula toruloidea infection: Successful response of onychomycosis to nail avulsion and topical ciclopirox olamine
10. A clinical and laboratory study of ciclopirox olamine (8% Batrafen) in the treatment of onychomycosis
11. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada: A multicenter survey of 2001 patients
12. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions
13. Onychomycosis is more than a cosmetic problem
14. Current management of onychomycosis
15. The new oral agents for onychomycosis of the toenails
16. An update, with a risk-benefit evaluation of the newer oral antifungal agents to treat onychomycosis
17. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial
18. Once-weekly fluconazole (150 mg, 300 mg, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail
19. Double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail
20. Pharmacokinetics of three doses of once-weekly fluconazole (1250, 300, and 450 mg) in distal subungual onychomycosis of the toenail
21. Nail incorporation kinetics of terbinafine in onychomycosis patients
22. Itraconazole and terbinafine in perspective. From petri dish to patient
23. Pharmacokinetics and biotransformation of the antimycotic drug ciclopirox olamine in animals and man after topical and systemic administration
24. Dermatopharmacology of ciclopirox nail lacquer 8% for the topical treatment of onychomycosis